US FDA approves Regeneron's ultra-rare blood disease drug
- S&P 500 and Nasdaq notch highest closes since early 2022
- U.S. economy adds 199,000 jobs in November
- Fed should 'lowball' rate cuts expectations next week says analyst after strong jobs data
- Bernstein's best idea for 2024? Short Tesla stock
- Analysts defend Broadcom as annual guidance falls short after FQ4 earnings beat
FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo
By Pratik Jain
(Reuters) -Regeneron Pharmaceuticals said on Friday the U.S. health regulator approved its drug to treat a rare blood disease.
The drug pozelimab, branded as Veopoz, would treat CHAPLE disease in adult and pediatric patients 1 year of age and older.
Veopoz — the first treatment to be approved by the U.S. Food and Drug Administration for the life-threatening disease — will be sold in the U.S. at a list price of $34,615.38 per single-use vial, the company told Reuters in an emailed response.
The drug will be available in the third quarter of this year, it said.
Regeneron said the disease has fewer than 10 patients identified in the U.S. and estimates less than 100 patients worldwide.
People with CHAPLE disease have mutated CD55 gene, which regulates the body's mechanism for destroying microbes. Without proper gene regulation, the mechanism may start attacking normal cells of the body.
Veopoz's approval, however, comes with a boxed warning for serious meningococcal infections, as the treatment poses risks of developing the life-threatening bacterial infection.
With Veopoz's approval, the company said the pre-approval inspection issues related to the marketing application of the higher dose of its blockbuster eye disease drug Eylea, or aflibercept, has been addressed.
The regulator's decision on the 8mg dose of Eylea is expected in the next few weeks, the company added.
Imminent approval would allow the company to quickly begin converting new patients to 8mg aflibercept ahead of biosimilar entrants, potentially preserve its Eylea franchise and future revenues from the high-dose version which could reach as high as $9.8 billion, according to BMO Capital Markets analyst Evan Seigerman.
Seigerman sees biosimilars for Eylea potentially able to enter the market in May 2024.
The FDA had in June declined to approve the higher-dose version following an inspection at third-party manufacturer Catalent.
(Reporting by Vaibhav Sadhamta, Khushi Mandowara and Pratik Jain in Bengaluru; Editing by Shilpi Majumdar)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease (CRSP) (VRTX) (BLUE)
- Onconova Therapeutics' (ONTX) Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's
- University of Pennsylvania president resigns after antisemitism testimony
Create E-mail Alert Related CategoriesFDA, General News, Reuters
Related EntitiesBMO Capital, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!